AstraZeneca to buy cancer drug firm for $440m


AstraZeneca, the UK’s second-largest drug maker, is set to boost its pipeline of cancer treatments after agreeing to buy privately-owned biotech firm Spirogen for up to $440 million (£275.4m).

The deal between AstraZeneca’s MedImmune subsidiary and London-based Spirogen comes less than two months after MedImmune sealed a $500m deal to buy US cancer drug specialist Amplimmune.

Spirogen was formed in 2001 as a spin-out from a number of institutions, including University College London, with partial funding from Cancer Research UK. It is majority owned by private equity firm Auven Therapeutics.

MedImmune is paying $200m up front for Spirogen, with a further payment of up to $240m depending on development progress.

The US-based company is also investing $20m in ADC Therapeutics, another oncology specialist in Auven’s portfolio, to collaborate on treatments.




Back to the top of the page




In partnership with

Complete coverage of the festivals. Guides. Reviews. Listings. Offers

Let's Go!

No Thanks